Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Silodosin,Tadalafil
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SUN Pharma Gets CDSCO Nod to Manufacture, Market FDC Silodosin JP Plus Tadalafil
Details : CDSCO has approved Silodosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil (PDE5 inhibitor), a fixed dose combination for the treatment of benign prostatic hyperplasia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : Silodosin,Tadalafil
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2022
Silodosin Versus Tamsulosin for Treatment of Ureteral Stones
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2015
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2014
Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 31, 2012
A Dose-finding Study of Silodosin in Patients With Urinary Calculi
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2012
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2012
Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2010
Lead Product(s) : Silodosin
Therapeutic Area : Urology
Study Phase : Phase IV
Sponsor : Chonnam National University Hospital | Kangdong Sacred Heart Hospital | Yeungnam University Hospital | Pusan National University Hospital | Seoul National University Hospital | Samsung Medical Center | Seoul St. Mary's Hospital | Korea University Guro Hos
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2010
Lead Product(s) : Silodosin
Therapeutic Area : Urology
Highest Development Status : Phase IV
Sponsor : Chonnam National University Hospital | Kangdong Sacred Heart Hospital | Yeungnam University Hospital | Pusan National University Hospital | Seoul National University Hospital | Samsung Medical Center | Seoul St. Mary's Hospital | Korea University Guro Hos
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2010